HeartWare vote for US move

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

Medical device company HeartWare [ASX: HTW] has received federal court approval to go ahead with shareholder meetings to vote on its plans to redomicile in the US.

Meetings are planned for October 22.

HeartWare has appointed BDO Kendalls Corporate Finance (QLD) to independently assess the proposed scheme. BDO has determined that the scheme is in the best interest of all stockholders.

Related News

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...

Content from other channels on our network

Increasing sensor life in harsh conditions

Enabling OT continuous monitoring

Central Coast Council completes first remote sewer inspection

Ghost Bat a major milestone for local defence manufacturing

From smart to vulnerable: The hidden costs of the digitalisation of utilities

Urinary incontinence and cardiovascular disease risk in women

Pharmacist distraction during dispensing — extent and sources

Ambulance ramping — its "very real potential human consequences"

Could this game wave goodbye to nerve pain?

Inaugural Hospital + Healthcare Excellence Awards — nominations open

GNT shows how plant-based colours can liven up snacks

Getting a handle on a shrink bag for turkey

Six on the shelf: from frozen snacks to GF treats

Visibly conveying freshly roasted coffee direct to the consumer

Sobering up with the latest wine trends

All content Copyright © 2025 Westwick-Farrow Pty Ltd